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   ABSTRACT 
  Objective      To examine the risk of serious infection 
conveyed by tumour necrosis factor α (TNFα) inhibitors 
in the treatment of rheumatoid arthritis (RA).   
  Methods      Data from patients with RA enrolled in the 
German biologics register RABBIT were used for analysis. 
Baseline patient characteristics, time-varying risk factors 
(treatment changes, functional capacity) and selection 
processes caused by dropout, death or switching to non-
anti-TNF treatment were taken into account to estimate 
the adjusted incidence rate ratios (IRR  adj  ) of serious 
infection during treatment with TNF inhibitors compared 
with non-biological disease-modifying antirheumatic drug 
treatment.  
  Results      Data were available on 5044 patients, in whom 
392 serious infections occurred. The crude rates of 
serious infections in patients treated with TNF inhibitors 
declined over the ﬁ  rst 3 years of observation (from 4.8 
to 2.2/100 patient-years). This decline was driven by (1) 
treatment termination or loss to follow-up in patients at 
increased risk and (2) a risk reduction through decreasing 
glucocorticoid doses and improvement in function. 
Adjusted for selection processes and time-varying risk 
factors, the following parameters assessed at baseline 
(age, chronic diseases) or at follow-up prior to the 
infection were signiﬁ  cantly associated with an increased 
risk: age >60 years, chronic lung or renal disease, 
low functional capacity, history of serious infections, 
treatment with glucocorticoids (7.5–14 mg/day, IRR  adj   2.1 
(95% CI 1.4 to 3.2); ≥15 mg/day, IRR adj   4.7 (95% CI 2.4 to 
9.4)) and treatment with TNFα inhibitors (IRR  adj   1.8 (95% 
CI 1.2 to 2.7)).   
  Conclusion      Reasons for the decline in infection rates 
observed at the group level were identiﬁ  ed. The results 
enable expected infection rates to be calculated in 
individual patients based on their risk proﬁ  les.           
  INTRODUCTION 
  A decade ago tumour necrosis factor (TNF) inhibi-
tors were approved for the treatment of rheumatoid 
arthritis (RA). Uncertainties regarding the speciﬁ  c 
risks of these new agents led to intensiﬁ  ed efforts 
to investigate their safety. Meta-analyses of ran-
domised controlled trials (RCTs) were undertaken, 
and various data sources including claims databases 
were used to assess the risk of serious adverse 
events (eg, serious infections) possibly associated 
with these agents.    1       –       11    One major innovation was 
the establishment of biologics registers to evaluate 
the safety and effectiveness of these drugs under 
the conditions of daily rheumatological care.    12    
Upon analysis of these data, it became increasingly 
clear that the question of how a drug affects the 
risk of a speciﬁ  c adverse event is far more com-
plex than evaluating the efﬁ  cacy of the drug. Some 
of the methodological difﬁ  culties we faced while 
analysing real-world data will be described in this 
paper using the example of examining how anti-
TNF therapy affects the risk of serious infection. 
  An increased rate of serious infections with anti-
TNF therapy compared with conventional disease-
modifying antirheumatic drug (DMARD) therapy 
was found in a meta-analysis of RCTs,    1    in an analy-
sis of claims data    8    and in observational data.    3        6        9    
Other ﬁ  ndings were in contrast to these results    2        10        11    
or reported a decline in the infection risk over time 
in patients treated with TNF inhibitors,    5        7        8        13    and 
therefore raised the question whether or not the 
risk is increased only during the ﬁ  rst months of 
treatment.    5        7        13    
  The ﬁ  rst aim of our study therefore was to deter-
mine whether or not there is a methodological or 
clinical explanation for this decline in risk and, if so, 
what the relative contributions might be. 
  Our second question was how the risk reduc-
tion seen in the cohorts is reﬂ  ected at the level 
of the individual patient. Patient demographics, 
clinical features and follow-up information such as 
treatment response and patient use of additional 
medications were studied to calculate the expected 
incidence rates of serious infections for deﬁ  ned 
subgroups of patients. The aim of this approach 
was to enable the treating physician to assess the 
magnitude of infection risk that he or she imposes 
on a patient when making speciﬁ  c  treatment 
decisions.   
  METHODS 
  Patients 
  The analysis was based on patients with RA 
enrolled in the German biologics register RABBIT, 
an ongoing prospective cohort study, at the start of 
treatment with a biological agent or a conventional 
DMARD, between 1 May 2001 and 31 December 
2006. Patients were followed up independent of 
any change in their treatment regimes. Observation 
time following a start of treatment with a non-anti-
TNF biological agent was excluded. Patients treated 
with anakinra at baseline (n=89) and those for 
whom only baseline data were available (n=141) 
were excluded.   
  ▶Additional data are published 
online only. To view the ﬁ  le 
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for differences between the anti-TNF and DMARD groups at 
the start of treatment (confounding by indication). A propensity 
score, as described earlier,    18    was used for adjustment. Further 
adjustment was made for risk factors for infection (  table 3  ). 
In model B we also considered changes in glucocorticoid dos-
age and changes in functional status during follow-up as time-
varying covariables. The differences between models A and B in 
the estimates of the trend parameter were used to calculate the 
relative contribution of clinical improvement to the decreased 
risk of infection. In the fully adjusted model C, generalised esti-
mation equations (GEEs) were applied to a weighted sample of 
patients. In addition to model B, this model takes into account 
confounding by anti-TNF treatment termination, the impact of 
dropout and previous serious infections.    19    We deﬁ  ned ‘dropout’ 
as either loss to follow-up, death or switching to non-anti-TNF 
therapy.   
  For each patient and each 6-month follow-up period we cal-
culated the probability of being in a certain status. Using logistic 
regression we estimated the probabilities of being a dropout with 
and without accounting for gender and patient characteristics at 
follow-up (occurrence of serious infections, DAS28, functional 
status). We calculated weights as ratios of both probabilities. The 
weights for different time periods were combined as described 
in detail by Molenberghs   et al  .    20    Again, for each 6-month period 
  Assessments 
  At baseline and at predeﬁ  ned points of follow-up (at 3, 6 months 
and thereafter every 6 months), rheumatologists assessed the 
clinical status of the patient including the components of the dis-
ease activity score based on 28-joint counts (DAS28),    14    reported 
treatment details and adverse events. Patients assessed, among 
other items, their functional capacity as a percentage of full func-
tion by means of the Hannover Functional Status Questionnaire 
(Funktionsfragebogen Hannover (FFbH)).    15        16    Reasons for dropout 
from the study and causes of death were ascertained by contacting 
health authorities. Follow-up data (including serious infections) 
reported prior to 1 November 2009 were included. An infec-
tion was attributed to anti-TNF treatment when the treatment 
was either ongoing or terminated ≤3 months prior to infection. 
A patient who switched from anti-TNF treatment to treatment 
with non-biological DMARDs contributed to anti-TNF exposure 
time until 3 months after switching and to DMARD exposure 
time thereafter. A DMARD-treated patient who switched to anti-
TNF treatment also contributed time to both exposure groups (for 
further details see Strangfeld   et al      17    or Listing   et al      3   ).   
  Statistical  analysis 
  Three different statistical models developed in a complemen-
tary fashion were used. In model A we adjusted the data only 
  Table  2         Crude rates of serious infections per 100 patient-years (pyrs)   
 Serious  infections 
 Incidence  rate 
ratio (IRR)      Exposure time (pyrs)   n    Per 100 pyrs   95%  CI 
Year 1
DMARD treatment 1765 40 2.3 1.6 to 3.1 2.13
Anti-TNF agents 3041 147 4.8 4.1 to 5.7
Year 2
DMARD treatment 1696 40 2.4 1.7 to 3.2 1.36
Anti-TNF agents 2564 82 3.2 2.9 to 4.0
Year 3
DMARD treatment 1397 35 2.5 1.8 to 3.5 0.88
Anti-TNF agents 2186 48 2.2 1.6 to 2.9  
      DMARD, disease-modifying antirheumatic drug; TNF, tumour necrosis factor.     
  Table  1       Baseline  characteristics  of  patients  
 Unweighted  sample   Weighted  sample 
   Anti-TNF   DMARD   Total   p  Value   Anti-TNF   DMARD   p  Value 
N 3271 1773 5044  3271 1773  
Weights, mean (SD) 1 (0) 1 (0) 1 (0) – 0.99 (0.8) 1.0 (1.2) 0.15
Female, n (%) 2556 (78.1) 1394 (78.6) 3950 (78.3) 0.69 2612.2 (78.8) 1519.4 (77.6) 0.29
Age 53.8 (12.3) 56.2 (11.5) 54.6 (12.1) <0.0001 54.4 (12.3) 54.6 (12.1) 0.47
Median (IQR) disease duration, years 9 (5, 16) 6 (3, 12) 8 (4, 15) <0.0001 8 (4, 15) 8 (4, 16) 0.45
Median (IQR) follow-up, years 3.1 (2.1, 4.9) 3.3 (2.5, 5.0) 3.1 (2.4, 5.0) <0.0001 3 (2.2, 4.6) 3.5 (2.5, 5) <0.0001
Rheumatoid factor positive, n (%) 2624 (80.2) 1271 (71.7) 3895 (77.2) <0.0001 2620.4 (79.0) 1479.6 (75.5) 0.003
DAS28 5.7 (1.2) 5.1 (1.3) 5.5 (1.3) <0.0001 5.5 (1.3) 5.6 (1.3) 0.20
FFbH 57.0 (23.0) 66.6 (21.5) 60.4 (22.9) <0.0001 60.0 (22.8) 58.7 (24.3) 0.05
Smoking ever, n (%) 1027 (47.0) 585 (45.6) 1612 (46.4) 0.43 1036.1 (46.3) 621.1 (44.7) 0.36
No of previous DMARDs 3.3 (1.3) 1.8 (1.0) 2.8 (1.4) <0.0001 2.8 (1.4) 2.9 (1.5) 0.01
No of previous biologics 0.23 (0.6) 0.01 (0.1) 0.14 (0.4) <0.0001 0.17 (0.5) 0.10 (0.4) <0.0001
Glucocorticoids 7.5–14 mg/day, n (%) 1027 (31.4) 386 (21.8) 1413 (28.0) <0.0001 938.6 (30.0) 404.1 (25.4) <0.0001
Glucocorticoids ≥15 mg/day, n (%) 491 (15.0) 147 (8.3) 683 (12.7) <0.0001 465.5 (14.9) 146.6 (9.2) <0.0001
COPD, n (%) 162 (5.0) 87 (4.9) 249 (4.9) 0.94 168.9 (5.1) 86.8 (4.4) 0.28
Chronic lung diseases total, n (%) 246 (7.5) 112 (6.3) 358 (7.1) 0.11 247.7(7.5) 135.9 (6.9) 0.47
Chronic renal disease, n (%) 139 (4.3) 31 (1.8) 170 (3.4) <0.0001 156.1 (4.7) 56.8 (2.9) 0.001
      Values are mean (SD) unless otherwise speciﬁ  ed. 
  The weights estimated for the ﬁ  rst time period (0–6 months) were used to calculate the weighted sample (columns 6 and 7). 
  COPD, chronic obstructive pulmonary disease; DAS28, disease activity score based on 28 joint counts; DMARD, disease-modifying antirheumatic drug; FFbH, Hannover Functional 
Status Questionnaire measuring functional capacity as percentage of full function; TNF, tumour necrosis factor.     
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multiplication to a ﬁ  nal weight. By using this inverse probabil-
ity weighting we obtained balanced samples of patients treated 
with or without TNFα inhibitors and of patients who continued 
or discontinued follow-up. 
  The application of multivariate GEE models requires a sufﬁ  -
cient number of observed serious infections. We aimed to detect 
a ≥1.5-fold increase in infection risk caused by TNF inhibitors or 
a trend in risk of similar size (≤0.67=1/1.5) that would be com-
parable to other observations.    2    The number of serious infections 
observed in the ﬁ  rst and second years would therefore ensure 
sufﬁ  cient power (80%) for this analysis, whereas the total num-
ber of infections observed in the third year (n=83) was too low 
to achieve sufﬁ  cient power. Because multiple infections in indi-
vidual patients are not independent of each other, the GEE mod-
els require an estimate of intrapatient correlations. The number 
of these correlations increased considerably when the data were 
analysed for all 3 years. Therefore, a robust estimate of the 
3-year infection risk was not possible. For both reasons (the small 
number of events and the high number of intracorrelations), we 
restricted the multivariate analysis to the ﬁ  rst 2 years. 
  Owing to strict monitoring, information about DMARD 
or anti-TNF treatment exposure was complete in >99% of all 
patients. For all follow-up time points within the ﬁ  rst 2 years (in 
dropouts before their last visit), 5.6% of DAS28 scores, 3.7% of 
FFbH scores and 3.6% of glucocorticoid dosages were missing. 
These values were replaced using statistical imputation meth-
ods based on the expectation maximation algorithm.    20    SAS soft-
ware version 9.2 (PROC GLIMMIX, PROC MI) was used for the 
computations. p Values <0.05 were considered to be statistically 
signiﬁ  cant.     
  RESULTS 
    Patient characteristics and treatment status at study entry 
  Between 1 May 2001 and 31 December 2006, 5274 patients 
were enrolled in RABBIT of whom 5044 met the inclusion cri-
teria for this study. The average follow-up time was 2.6 years. 
Upon enrolment, patients treated with TNFα inhibitors differed 
signiﬁ  cantly from those receiving conventional DMARDs with 
regard to age, disease duration, disease activity (DAS28), func-
tional capacity (FFbH) or number of failed previous DMARD 
treatments (  table 1  , columns 2–5). The proportion of patients 
receiving higher doses of glucocorticoids was also signiﬁ  cantly 
different. Inverse probability weighting was used for the ﬁ  nal 
analysis and allowed for balanced anti-TNF and DMARD sam-
ples (  table 1  , columns 6–8).   
    Trends in crude infection rates 
  The crude rates of serious infections decreased signiﬁ  cantly from 
the ﬁ  rst to the second and third years in patients treated with TNF 
inhibitors, whereas these rates remained stable in the cohort of 
DMARD-treated patients (  table 2  ). The decrease in the absolute 
rates of infection in patients treated with TNF inhibitors led to a 
decrease in the relative rates or incidence rate ratios (IRRs).   
    Changes in patient risk proﬁ  les over time 
  Overall, 1893 patients dropped out because of loss to follow-up, 
death or changing to non-anti-TNF biological agents within 3 
years (  ﬁ  gure  1  ). Dropouts experienced a signiﬁ  cantly  greater 
number of serious infections during the 6 months prior to drop-
ping out than the patients who remained in the study. This 
association remained signiﬁ  cant after adjustment for other risk 
factors of dropping out (male gender, elevated DAS28 scores, 
poor functional capacity) and repeated signiﬁ  cance testing. The 
the likelihood of being treated with anti-TNF agents was cal-
culated by taking and not taking into account covariables (age, 
number of DMARD failures and the patient characteristics listed 
above). This resulted in weights which account for treatment 
decisions.    19        20    Both types of weights (for dropout and treatment 
groups) were uncorrelated (|r|<0.1)   and were then combined by 
 Figure  1         Flow chart of patients who dropped out of observation 
with rates of serious infections in patients who continued and those 
who dropped out. Dropouts include patients who switched to non-
anti-tumour necrosis factor biological agents. IR, incidence rate; SINF, 
number of serious infections.       
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decrease in crude IRRs (  table 2  ). However, model A disregards 
the considerable changes in glucocorticoid dose during the fol-
low-up period (  ﬁ  gure 2  ) and therefore misclassiﬁ  es exposure 
at follow-up. Taking into account the time-varying change of 
glucocorticoid dose and the improvement in functional capacity 
(model B), approximately one-third (1 − (1 − 0.79)/(1 − 0.69)) of 
the decrease observed in model A can be attributed to the efﬁ  -
cacy of TNF inhibitors. Dropout and treatment changes (either 
to non-anti-TNF biological agents or from anti-TNF to conven-
tional DMARD treatment) in patients at risk of infection are 
responsible for the remaining two-thirds of the decline. 
  The additional adjustment for dropout processes and treat-
ment adaptations in model C led to changes in the IRRs com-
pared with model B which were observed in the expected 
direction (  table 3  ). Overall, these changes resulted in an IRR for 
trend of 1.0, suggesting that there is no time-dependent decline 
in the risk of infection with TNF inhibition if all risk factors are 
controlled for (  table 3  ). 
  We found a signiﬁ  cantly increased risk of serious infection in 
patients who had already developed a serious infection earlier 
in the observation period. Furthermore, older age, chronic lung 
disease, chronic renal disease and a high number of previous 
treatment failures increased the risk, whereas a good functional 
status reduced the risk. The risk was signiﬁ  cantly increased in 
adjusted OR for dropping out after a serious infection calculated 
for each 6-month period ranged from 2.7 (95% CI 1.2 to 6.2) to 
4.7 (95% CI 2.5 to 8.8).   
  Furthermore, patients who developed serious infections were 
more likely to switch from anti-TNF treatment to DMARD 
treatment. Since patients with prior serious infection were at 
increased risk of developing a further serious infection (see 
below), this switching led to changes in the risk proﬁ  les of the 
treatment groups (data not shown). 
  Another factor leading to a change in patient risk proﬁ  le was 
the decreasing number of patients who received higher doses of 
glucocorticoids. The decline in the percentage of patients who 
needed this additional treatment was far more pronounced in 
the anti-TNF group (  ﬁ  gure 2  ).     
  Multivariate  analysis 
  To estimate the relative contributions of changes in the clini-
cal status of the patients and of selection processes to the time-
varying risk of infection, we applied three different statistical 
models (see Methods section). Based on model A which adjusted 
only for the baseline characteristics of the patients, we observed 
a statistically signiﬁ  cant 31% decrease in the IRRs from year 1 
to year 2 in the anti-TNF treatment group compared with the 
DMARD group (  table 3  ). This decrease was comparable to the 
 Figure  2         Decline in co-medication with glucocorticoids in patients who received a dose of (A) 7.5–14 mg/day or (& ) ! 15 mg/day. DMARD, disease-
modifying antirheumatic drug; TNF, tumour necrosis factor.       
  Table  3          Adjusted incidence rate ratios (IRR) of developing a serious infection in the ﬁ  rst or second year   
 Model  A   Model  B    Fully adjusted model C 
   IRR   95%  CI   IRR   95%  CI   IRR   95%  CI   p  Value 
Age >60 years (yes vs no) 1.7 1.3 to 2.3 1.7 1.3 to 2.3 1.6 1.1 to 2.4 0.012
Chronic lung disease (yes vs no) 2.6 1.8 to 3.7 2.3 1.6 to 3.3 1.7 1.1 to 2.6 0.014
Chronic renal disease (yes vs no) 2.3 1.5 to 3.7 2.1 1.3 to 3.3 1.6 0.9 to 2.8 0.14
High number of treatment failures (>5) at baseline (yes vs no) 1.2 0.8 to 1.7 1.1 0.8 to 1.6 1.6 1.1 to 2.3 0.027
History of serious infection at follow-up (yes vs no) –   –   2.1 1.0 to 4.3 0.038
FFbH (0–100%) per 10% at baseline 0.92 0.87 to 0.98          
FFbH (0–100%) per 10% at follow-up     0.90 0.86 to 0.95 0.90 0.85 to 0.96 0.0023
Glucocorticoids 7.5–14 mg/day at baseline (yes vs no) 1.0 0.7 to 1.4          
Glucocorticoids 7.5–14 mg/day at follow-up (yes vs no)     1.9 1.4 to 2.6 2.1 1.4 to 3.2 0.0002
Glucocorticoids ≥ 15 mg/day at baseline (yes vs no) 1.5 1.0 to 2.1          
Glucocorticoids ≥ 15 mg/day at follow-up (yes vs no)     3.6 2.2 to 5.7 4.7 2.4 to 9.4 <0.0001
Treatment with TNF inhibitors (yes vs no) 1.6 1.2 to 2.3 1.6 1.2 to 2.3 1.8 1.2 to 2.7 0.0027
Trend (IRR TNF year 2/IRR TNF year1) 0.69 0.50 to 0.96 0.79 0.57 to 1.10 (1.0) (0.5 to 2.0) (0.93)
      Model A: only baseline characteristics were used for calculation and adjustment. 
  Model B: time-dependent use of glucocorticoids and FFbH were considered in the model. No adjustment for DMARD/anti-TNF treatment adaptations and dropout processes at 
follow-up. 
  Model C: fully adjusted model. Adjustment for time-varying risk factors as in model B and for treatment adaptations and dropout processes (see Methods section for further details). 
  DMARD, disease-modifying antirheumatic drug; FFbH, Hannover Functional Status Questionnaire measuring functional capacity as percentage of full function; TNF, tumour necrosis 
factor.   
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were actually observed in these 70 patients. A similar result was 
found for the 39 DMARD-treated patients in whom three seri-
ous infections were observed and 3.7 (95% CI 1.6 to 8.5) were 
predicted by the model.     
  DISCUSSION 
  Long-term safety data from observational studies reﬂ  ect time-
dependent changes in the risk proﬁ  les of individual patients as 
well as changes in the composition of the cohorts. Our study 
shows how variable the results from these studies can be, 
depending on the statistical model applied to adjust for differ-
ences between groups. 
  Using our statistical model A, we saw a similar decline in the 
absolute and relative risk of infection in the anti-TNF group in 
the second year of treatment, as has been reported from other 
observational data.    5        7        13    Taking into account changes in clinical 
status (model B) and the effect of treatment changes and drop-
outs (model C), we were able to explain this decrease and to 
estimate the relative contributions of both processes. We found 
that approximately one-third of the decrease in risk was caused 
by improvement in the clinical status and reduction of concomi-
tant glucocorticoid therapy (mirroring a reduction of risk in indi-
vidual patients). The remaining two-thirds of the decrease in risk 
could be explained by selective switching of patients who were 
at increased risk of infection. Both processes (clinical improve-
ment and depletion of susceptible patients) led to a ‘healthy drug 
survivor effect’ in the anti-TNF cohort—that is, those patients 
who did well and responded to treatment remained under ther-
apy. Of note, such a ‘healthy drug survivor effect’ is also present 
in extension studies of RCTs and might explain the contrasting 
results of two meta-analyses.    1        2    With regard to the question as 
to what are the risk factors of serious infection, we found that 
age, functional status and comorbidity contributed signiﬁ  cantly 
to the overall infection risk, in addition to treatment with TNF 
inhibitors or glucocorticoids. 
  The adjusted relative risk of treatment with TNF inhibi-
tors compared with that of conventional DMARDs was 1.8. 
patients treated with glucocorticoids in a dose of ≥15 mg/day 
(IRR=4.7) or 7.5–14 mg/day (IRR=2.1) and in patients treated 
with TNF inhibitors (IRR=1.8). No signiﬁ  cant increase in risk 
was observed for treatment with lower doses of glucocorticoids 
(IRR=1.1 (0.8; 1.7)) or in patients with other co-morbid condi-
tions (eg, diabetes, IRR=1.3 (0.8; 2.0)). Higher disease activity 
was not directly associated with an increased infection risk but 
indirectly via the use of glucocorticoids and decline in function.   
    Absolute risks in different groups of patients 
  The fully adjusted model C allows estimation of relative risks 
(IRRs) and also the calculation of expected incidence rates of 
serious infection for individual patients depending on their risk 
proﬁ  les. As the IRRs of model C are not time-dependent, these 
incidence rates are also not time-dependent. They only change in 
a patient when the risk factors she or he is exposed to change. 
  The rates shown in   ﬁ  gure 3   (and in ﬁ  le 1 in the online supple-
ment) reﬂ  ect how the infection risk in an individual patient is 
inﬂ  uenced by treatment with different doses of glucocorticoids 
or by treatment with anti-TNF agents compared with DMARDs. 
The rates further describe how the risk increases if a patient has 
one, two or three risk factors for serious infection (greater age, 
comorbid conditions such as chronic lung disease or chronic 
renal disease, or history of serious infection). The risk of infec-
tion increases steadily with the number of risk factors and with 
the dose of glucocorticoids, both in the anti-TNF and DMARD 
treatment groups.   
  The number of patients with two or more risk factors and 
treatment with glucocorticoids in a dose of ≥15 mg/day was 
rather low (70 exposed to anti-TNF, 39 treated with DMARDs). 
Nevertheless, the estimated incidence rates from model C were 
in accordance with the observed incidence rates in these patients. 
Taking into account the duration of exposure to high-dose glu-
cocorticoids, the speciﬁ  c risk factors and the functional capacity 
of these patients, we would have expected 12.8 (95% CI 6.0 to 
27.6) serious infections in patients exposed to anti-TNF agents. 
This modelling aligned well with the 13 serious infections that 
 Figure  3         Estimated incidences of serious infections in 100 patients per year by treatment and risk proﬁ  le. Additional risk factors are one or two of 
the following: age >60 years, chronic lung disease, chronic renal disease or high number of treatment failures; three risk factors: two of the above 
risk factors plus prior serious infections. DMARD, disease-modifying antirheumatic drug; TNFi, tumour necrosis factor inhibitor.    
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Furthermore, the adjusted relative risk of glucocorticoids was 
2.1 for a dose of ≥7.5 mg/day and 4.7 for a dose of ≥15 mg/day. 
This result underlines the high risk conveyed by glucocorticoids 
that has also been addressed by other researchers.    8       –       11        21        22    
  The risk imposed on a patient by one treatment must be bal-
anced against the risk conferred by an alternative treatment. 
For example, consider a patient with highly active RA, aged 65, 
treated with methotrexate and 10 mg/day glucocorticoids. This 
patient has an ‘average’ risk of developing 0.032 serious infec-
tions per year. This risk increases to 0.058 if anti-TNF treatment 
is started, but it may decrease to 0.027 if glucocorticoid treat-
ment can be reduced below 7.5 mg/day due to the response to 
anti-TNF treatment. The number needed to harm in this exam-
ple decreases from 1 out of 31 with DMARD treatment plus 
10 mg glucocorticoids to 1 out of 17 after start of anti-TNF and 
increases again to 1 out of 37 after stopping glucocorticoid treat-
ment and maintaining TNF inhibition. 
  According to our data, improvement in function as a result 
of effective treatment can reduce the risk of serious infection 
signiﬁ  cantly and to a greater extent than improvement in dis-
ease activity measured by the DAS28. This result is clinically 
plausible when one considers that immobility is a strong risk 
factor for developing comorbidities such as pneumonia or 
urogenital infections. Cardiovascular risk factors, as discussed 
prepviously,    7        10    are linked to age and were therefore not identi-
ﬁ  ed in our data. 
  Our analysis has some limitations. We investigated only the 
overall infection risk and were therefore not able to consider 
site-speciﬁ  c risk factors. There was also limited statistical power 
to analyse the data from the third year. We did not investigate 
the three TNF inhibitors separately. Although different effects 
on the reactivation of tuberculosis    23    and viral infections    17    have 
been reported for adalimumab, inﬂ  iximab and etanercept, the 
overall infection risk appears to be similar.    3        5        13    
  The important message from this study to the practising phy-
sician is that the time-dependent decline in risk seen in cohorts 
of patients treated with anti-TNF agents is partially caused by 
changes in the case mix of these cohorts and cannot directly 
be transferred to individual patients. Independent of treatment 
duration, TNF inhibition imposes an increased risk of serious 
infection on a patient which must be balanced against other 
risks resulting from co-medication, in particular higher doses of 
glucocorticoids and active disease. 
  Our data provide, for the ﬁ  rst time, detailed information about 
the expected absolute risk of serious infection in subgroups of 
patients. This work therefore helps rheumatologists to identify 
patients at increased risk and to avoid combinations of treat-
ments that confer a very high risk in predisposed patients.         
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